VUNO Collaborates with European Firms to Expand DeepCARS® in Europe
VUNO Inc., a prominent player in the medical AI field, has taken a significant step in its international expansion by entering into a strategic partnership with two notable European firms: Contextflow and Mesalvo. This collaboration, formalized through a Memorandum of Understanding (MOU), is designed to facilitate the introduction of VUNO Med®–DeepCARS®, an advanced AI solution for predicting cardiac arrests, into the European healthcare market.
The MOU was signed on October 27, 2025, during the 38th annual Congress of the European Society of Intensive Care Medicine (ESICM LIVES 2025) in Munich, Germany. This event served as an ideal platform for VUNO to showcase the capabilities of DeepCARS while reinforcing its commitment to enhancing patient care through innovative technology.
VUNO Med®–DeepCARS® functions by analyzing patients' vital signs, including blood pressure, heart rate, respiratory rate, and body temperature, to identify those at risk of in-hospital cardiac arrest within the next 24 hours. This timely intervention could significantly improve patient outcomes, a message that VUNO illustrated at the ESICM conference with its slogan "Predict Early, Prevent More."
With DeepCARS already implemented in over 50,000 hospital beds across South Korea, including major tertiary hospitals, VUNO aims to replicate this success in European healthcare systems. The partnership with Contextflow will enhance its market access, leveraging Contextflow's proficiency in navigating the reimbursement landscape for imaging AI solutions within Europe, ensuring that DeepCARS meets all regulatory requirements.
In addition, Mesalvo, a well-established provider of hospital information systems in Europe, will focus on integrating DeepCARS into its electronic health record (EHR) systems. This alignment is critical, as it positions DeepCARS to potentially benefit more than 900 hospitals in the region, thereby expanding its reach and impact significantly.
Dr. Ye Ha Lee, the founder and CEO of VUNO, expressed enthusiasm regarding the partnership, stating, "This strategic MOU with Contextflow and Mesalvo marks a significant step toward DeepCARS' expansion into Europe. By working closely with trusted local partners, we aim to set a new global standard in AI-based patient care that European hospitals and medical professionals can rely on."
VUNO's mission to provide accessible, high-quality healthcare is evidenced by its ongoing innovations. As the first South Korean company to receive FDA's Breakthrough Device Designation for DeepCARS, VUNO continues to prioritize patient-centered care, utilizing advanced AI technology to analyze diverse medical data streams. This innovative approach supports healthcare providers in making informed decisions that can drive effective patient outcomes.
Furthermore, VUNO remains dedicated to expanding its technological prowess by continually refining DeepCARS through real-world validations and by developing reimbursement strategies in collaboration with European entities. These actions not only bolster the presence of DeepCARS in the competitive medical landscape but also signify VUNO’s broader ambitions in the realm of global health technology.
In conclusion, VUNO's partnership with Contextflow and Mesalvo is a pivotal step towards realizing the potential of DeepCARS across Europe. With AI technology at the forefront of healthcare innovation, VUNO is poised to make substantial improvements in patient care, underscoring the critical need for timely, effective interventions in emergency health scenarios.
The MOU was signed on October 27, 2025, during the 38th annual Congress of the European Society of Intensive Care Medicine (ESICM LIVES 2025) in Munich, Germany. This event served as an ideal platform for VUNO to showcase the capabilities of DeepCARS while reinforcing its commitment to enhancing patient care through innovative technology.
VUNO Med®–DeepCARS® functions by analyzing patients' vital signs, including blood pressure, heart rate, respiratory rate, and body temperature, to identify those at risk of in-hospital cardiac arrest within the next 24 hours. This timely intervention could significantly improve patient outcomes, a message that VUNO illustrated at the ESICM conference with its slogan "Predict Early, Prevent More."
With DeepCARS already implemented in over 50,000 hospital beds across South Korea, including major tertiary hospitals, VUNO aims to replicate this success in European healthcare systems. The partnership with Contextflow will enhance its market access, leveraging Contextflow's proficiency in navigating the reimbursement landscape for imaging AI solutions within Europe, ensuring that DeepCARS meets all regulatory requirements.
In addition, Mesalvo, a well-established provider of hospital information systems in Europe, will focus on integrating DeepCARS into its electronic health record (EHR) systems. This alignment is critical, as it positions DeepCARS to potentially benefit more than 900 hospitals in the region, thereby expanding its reach and impact significantly.
Dr. Ye Ha Lee, the founder and CEO of VUNO, expressed enthusiasm regarding the partnership, stating, "This strategic MOU with Contextflow and Mesalvo marks a significant step toward DeepCARS' expansion into Europe. By working closely with trusted local partners, we aim to set a new global standard in AI-based patient care that European hospitals and medical professionals can rely on."
VUNO's mission to provide accessible, high-quality healthcare is evidenced by its ongoing innovations. As the first South Korean company to receive FDA's Breakthrough Device Designation for DeepCARS, VUNO continues to prioritize patient-centered care, utilizing advanced AI technology to analyze diverse medical data streams. This innovative approach supports healthcare providers in making informed decisions that can drive effective patient outcomes.
Furthermore, VUNO remains dedicated to expanding its technological prowess by continually refining DeepCARS through real-world validations and by developing reimbursement strategies in collaboration with European entities. These actions not only bolster the presence of DeepCARS in the competitive medical landscape but also signify VUNO’s broader ambitions in the realm of global health technology.
In conclusion, VUNO's partnership with Contextflow and Mesalvo is a pivotal step towards realizing the potential of DeepCARS across Europe. With AI technology at the forefront of healthcare innovation, VUNO is poised to make substantial improvements in patient care, underscoring the critical need for timely, effective interventions in emergency health scenarios.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.